Liquid biotech funds with significant outperformance

The Aescap funds significantly outperform their benchmarks due to a concentrated portfolio with strictly selected high-growth companies active in growth sectors with a high unmet medical need, using AI to drive medical innovation.

Scroll

In short

Invest in groundbreaking life sciences products

By combining deep company analysis with a disciplined investment strategy, we significantly outperform our informal benchmarks*. Join the Aescap investment team in investing in a sector with strong and sustainable growth drivers.

The Aescap funds consist of high-conviction portfolios of approximately 20 carefully selected companies, each distinguished by proprietary technology and products with a robust competitive edge.

*From the fund’s inception to the end of 2025, the fund has outperformed the iShares Biotech ETF by 53% in EUR

Discover our funds →

The Market

Rapidly growing demand for more better treatments

Demand for more effective and more convenient therapies is rising rapidly due to an aging population, the desire to live healthier for longer, and the increasing costs associated with diseases like Alzheimer’s, Parkinson’s, and MS.

Although medicines represent only ~6% of total healthcare expenditures, they remain one of the most effective ways to reduce per-patient healthcare costs.

Momentum

AI accelerates development & reduces costs

The Aescap funds focus on biotech companies leading the application of AI in research and development. These companies shorten development timelines, reduce costs, improve clinical success rates, and strengthen their competitive advantage.

Our experienced investment team – with several professionals each possessing over thirty years of sector expertise – combines scientific depth with financial discipline.

Biotech as an investment

Why choose Aescap?

Investing in biotech requires in-depth knowledge and a disciplined approach. The Aescap funds offer both.

Selection of Highest Potential

From roughly 900 publicly listed biotech companies, the Aescap investment team selects the ~20 most promising for each fund. These are carefully chosen on the basis of the quality of management, distinctive medicines and an attractive valuation.

Diversification & Discipline

Exposure across technologies, disease areas, development stages, and geographic regions, all supported by disciplined investment and divestment processes.

Oversight & Structure

The fund manager, Privium Fund Management BV, is authorised and regulated by the AFM and DNB.

Aescap today

Track Record & Skin in the Game

Over the past ten years, Aescap Life Sciences has significantly outperformed its benchmark — the iShares Biotech ETF (IBB) in EUR. The investment team has personally invested more than €40 million in the Aescap funds.

Years of outperformance

€40M

Team's personal investment

~20

High-conviction positions per fund

Future Outlook

Why invest in biotech now?

Biotechnology is experiencing its most significant acceleration since the decoding of the human genome. Breakthroughs in AI, gene therapy, RNA and cell therapies, immuno-oncology, and personalized medicine are creating unprecedented opportunities.

Major institutional investors increasingly cite biotech as a core sector for the decades ahead. The structural need for better medicines is universal, and largely independent of economic cycles given medicine are paid for by health insurances.

Ready to invest in the future of healthcare?

Get in touch for a personal conversation or subscribe to our newsletter

Schedule an introductory meeting → Subscribe to our newsletter